Newly designed chimeric antigen receptor (CAR) T-cells targeting the CD19 antigen are effective in treating adults and children with B-cell malignancies, especially when produced under place-of-care manufacturing which is ...
Dec 20, 2021
0
3
Research from the Single-Cell Genomics Centre on the Wellcome Genome Campus could change the way we look at gene expression and immune response. Published in Nature Methods, the new method, TraCeR, provides a powerful tool ...
Mar 7, 2016
0
2
A team of molecular oncologists at Tsinghua University's State Key Laboratory of Molecular Oncology, in China, has found that engineered, long-lived and multifunctional T cells repress signs and symptoms of allergic asthma ...
Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according ...
Oct 19, 2023
0
1
To live with type 1 diabetes is to be ruled by relentless routine. Food must be carefully monitored, and the only treatment, subcutaneous insulin, is burdensome—requiring regular injections or an insulin pump, continuous ...
Sep 8, 2023
0
8
Immunotherapy has changed the way oncology patients are treated. Immunotherapy approaches, including the use of immunomodulatory agents to enhance anti-cancer responses and the recent development of adoptive cell therapies ...
Apr 21, 2022
0
5
A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according ...
Mar 31, 2019
0
1
New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining ...
Nov 7, 2023
0
1
Locally advanced cervical cancer remains an area of high therapeutic need, with recent trials failing to demonstrate evidence of benefit from adjuvant chemotherapy or immune checkpoint blockade administered concurrent with ...
Mar 27, 2023
0
8
Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the immune system. The investigators ...
Jul 18, 2019
0
6
